Claims for Patent: 8,536,126
✉ Email this page to a colleague
Summary for Patent: 8,536,126
Title: | Conjugated factor VIII molecules |
Abstract: | The present invention relates to B-domain truncated Factor VIII molecules with a modified circulatory half life, said molecule being covalently conjugated with a hydrophilic polymer. The invention furthermore relates to methods for obtaining such molecules as well as use of such molecules. |
Inventor(s): | Bolt Gert, Vandahl Brian Berg Stidsen, Thim Lars, Stennicke Henning Ralf, Steenstrup Thomas Dock, DeFrees Shawn |
Assignee: | Novo Nordisk A/S |
Application Number: | US13759261 |
Patent Claims: |
Details for Patent 8,536,126
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Novo Nordisk Inc. | ESPEROCT | antihemophilic factor (recombinant), glycopegylated-exei | For Injection | 125671 | February 19, 2019 | ⤷ Try for Free | 2033-02-05 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |